Lupin has received approval for divestment of its entire equity interest, representing 99.82% of the issued and paid up capital, in Kyowa Pharmaceutical Industry, Japan, a step-down material subsidiary of the Company, by Nanomi BV, a wholly owned material subsidiary of the Company, by way of sale of shares, to Plutus, Japan (an entity affiliated with Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), LP) at an enterprise value of JPY 57,361 million on terms and conditions agreed under a share purchase agreement. The Board of Directors of the Company at its meeting held on November 11, 2019 has approved the same.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
